Skip to main content
Equibles
PHAT logo

PHAT · Phathom Pharmaceuticals, Inc.

Track PHAT — free Ask ALVIS about PHAT
$11.64 -0.02 (-0.17%) At close · Jul 29 Earnings today
Market Cap
$928.36M
Shares
79.76M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.64 Open$11.92 Day$11.60–12.00 52W$8.03–18.31 Avg vol 30d1.1M Short int12.1M · 15.2% float · 9.0d Short vol54% Last earningsJul 30, 2026 DataJan 2020–Jul 2026 Filing10-Q · Apr 30

Up next

Earnings call today
Jul 30, 2026 Today
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Apr 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 20.7 · elevated Equity put/call 0.61
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −8%
      below
      Price vs 50-day avg +7%
      above
      RSI (14) 55
      neutral
      MACD trend Positive
      52-week position 35%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +7%
      trailing
      6-month return −12%
      trailing
      YTD return −30%
      this year
      Relative strength −18%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $11 › 200d $13 — 200d above 50d
      Institutional flow Accumulating
      27 of 175 funds reported for Jun 30 · net +173.6K sh shares · +2 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      15.20% of float · ▲ +1.1% MoM · 9.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      175 holders — near 3-yr high, broad support
      Squeeze score 90
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +217%
      Y/Y
      Gross margin 87%
      expanding
      EPS growth +43%
      Y/Y
      Free cash flow $-167.0M
      Balance sheet $79.1M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 61%
      annualized · 1-yr
      Max drawdown −49%
      past year
      ATR 5.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Mar 31, 2026
      Net revenue · 2026 Maintained $320M – $345M
      prior FY $175.11M midpoint +89.9% Y/Y
      Gross to net discount · 2026 Maintained 55% – 59%
      Gross margin · 2026 Maintained 80%
      Cash operating expenses, excluding stock-based compensation · 2026 Non-GAAP Initiated $235M – $255M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −8% Bearish
      Price vs 50-day avg
      +7% Bullish
      RSI (14)
      55 Neutral
      MACD trend
      Positive Bullish
      52-week position
      35% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $11 › 200d $13 — 200d above 50d
      Institutional flow Accumulating
      27 of 175 funds reported for Jun 30 · net +173.6K sh shares · +2 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      15.20% of float · ▲ +1.1% MoM · 9.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      175 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $8 Now $12 · 35% 52-wk high $18
      vs 200-day avg -8% vs 50-day avg +7%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Covered prescriptions year-over-year growth 91% first quarter 2026 —
      Total VOQUEZNA prescriptions filled in the first quarter 268,000 first quarter 2026 —
      Covered prescriptions growth 21% the fourth quarter —
      Net cash usage 5.2M the fourth quarter —
      Non-GAAP operating expenses non-GAAP 283.8M the full year —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PHAT
      Phathom Pharmaceuticals, Inc.
      this stock
      		$928.36M -29.8% +8001.5% — 15.2%
      ONC
      BeOne Medicines Ltd.
      		 $472.90B +7.7% +22179.2% 962.4 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $122.67B +6.6% +46.2% 28.7 2.0%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $72.91B -9.8% +20.8% 17.0 3.3%
      ARGX
      Argenx SE
      		 $54.57B +4.9% — — 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      170
      % held
      87.1%
      Reported
      27 of 175
      Top holder
      Frazier Life Sciences Man…
      Held Float
      View
      Held by Funds
      Fund positions
      160
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      12.1M
      Days to cover
      9.0d
      Change
      +128.1K sh
      View
      Short Volume
      Short vol %
      54%
      As of
      Jul 29, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      49.0K
      Value
      $532.8K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      50.0%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $175.1M
      Net income (FY)
      $-221.2M
      EPS diluted
      $-3.03
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      12
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 30, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PHAT -0.5% +7.3% -12.0% +7.3% -29.8%
      SPY -2.4% -2.3% +6.3% -2.3% +7.0%
      vs SPY +1.9% +9.6% -18.3% +9.6% -36.8%
      Key facts CIK 1783183 CUSIP 71722W107 13F (30d) 22 filings 22 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)